#### 1 Impact of Cerebrospinal Fluid Leukocyte Infiltration and Neuroimmmune Mediators on

# 2 Survival with HIV-Associated Cryptococcal Meningitis

- <sup>3</sup> Samuel Okurut <sup>1,2\*</sup>, David R. Boulware <sup>3</sup>, Yukari C. Manabe <sup>1,4</sup>, Lillian Tugume <sup>1</sup>, Caleb P.
- <sup>4</sup> Skipper<sup>3</sup>, Kenneth Ssebambulidde<sup>1</sup>, Joshua Rhein<sup>3</sup>, Abdu K. Musubire<sup>1</sup>, Andrew Akampurira
- <sup>5</sup> <sup>1,2</sup>, Elizabeth Okafor <sup>3</sup>, Joseph O. Olobo <sup>5</sup>, Edward N. Janoff <sup>6,7</sup>, and David B. Meya <sup>1,3,8</sup> for
- 6 ASTRO Trial Team.
- 7 <sup>1</sup> Research Department, Infectious Diseases Institute, Makerere University, Kampala, Uganda
- 8 <sup>2</sup> Department of Medical Microbiology, School of Biomedical Sciences, College of Health
- 9 Sciences, Makerere University, Kampala, Uganda
- 10 <sup>3</sup> Division of Infectious Diseases and International Medicine, Department of Medicine,
- 11 University of Minnesota, Minneapolis, MN, USA

<sup>4</sup> Division of Infectious Diseases, Department of Medicine, John Hopkins University School of

- 13 Medicine, Baltimore, Maryland, MD, USA
- <sup>5</sup> Department of Immunology and Molecular Biology, School of Biomedical Sciences, College
- 15 of Health Sciences, Makerere University, Kampala, Uganda
- <sup>6</sup> Mucosal and Vaccine Research Program Colorado, Department of Medicine, Division of
- 17 Infectious Diseases, University of Colorado Denver, Aurora, Colorado, CO. USA
- 18 <sup>7</sup> Rocky Mountain Regional Veterans Affairs Medical Center, Aurora CO, USA
- 19 <sup>8</sup> Department of Medicine, School of Medicine, College of Health Sciences, Makerere
- 20 University, Kampala, Uganda
- 21 Correspondence to: Samuel Okurut, Infectious Diseases Institute, College of Health Sciences,
- 22 Makerere University, Box 22418, Kampala, Uganda. Email: <u>okuruts@gmail.com</u>, Mobile:
- 23 +256 782, 003931

#### 24 Word count: 3,121 words

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 25 Abstract (220 words)

Introduction: Cryptococcal meningitis remains a prominent cause of death in persons with
 advanced HIV disease. CSF leukocyte infiltration predicts survival at 18 weeks; however, how
 CSF immune response relates to CSF leukocyte infiltration is unknown.

29 Methods: We enrolled 401 adults with HIV-associated cryptococcal meningitis in Uganda 30 who received amphotericin and fluconazole induction therapy. We assessed the association of

- 31 CSF leukocytes, chemokine, and cytokine responses with 18-week survival.
- 32 **Results:** Participants with CSF leukocytes  $\geq$  50/µL, had higher probability 68% (52/77) of 18-

33 week survival compared with 52% (151/292) 18-week survival in those with  $\leq$ 50 cells/ $\mu$ L

34 (Hazard Ratio=1.63, 95% confidence intervals 1.14-2.23; p=0.008). Survival was also

35 associated with higher expression of T helper (Th)-1, Th17 cytokines, and immune regulatory

36 elements. CSF levels of Programmed Death-1 Ligand, CXCL10, and Interleukin (IL)-2

- 37 independently predicted survival. In multivariate analysis, CSF leukocytes were inversely
- 38 associated with CSF fungal burden and positively associated with CSF protein, interferon-
- 39 gamma (IFN- $\gamma$ ), IL-17A, tumor necrosis factor (TNF)- $\alpha$ , and peripheral blood CD4<sup>+</sup> and CD8<sup>+</sup>
- 40 T cells expression.
- 41 **Conclusion:** 18-week survival after diagnosis of cryptococcal meningitis was associated with
- 42 higher CSF leukocytes at baseline with greater T helper 1 (IFN- $\gamma$ , IL-2 and TNF- $\alpha$  cytokines),

43 T helper 17 (IL-17A cytokine) and CXCR3<sup>+</sup> T cell (CXCL10 chemokine) responses. These

44 results highlight the interdependent contribution of soluble and cellular immune responses in

45 predicting survival with HIV-associated cryptococcal meningitis.

- Keywords: CSF white cells, cerebrospinal fluid, chemokines, cytokines, HIV-associated
   cryptococcal meningitis, survival, fungal burden, antifungal therapy, immune response
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56

#### 57 1. Background

58 Cryptococcal meningitis (CM) remains one of the leading causes of AIDS-related death 59 worldwide[1-3]. Cryptococcal infection of the central nervous system (CNS) leads to activation of CNS-resident and patrolling immune cells [4-6]. Activated leukocytes in 60 61 cerebrospinal fluid (CSF) produce chemokines, cytokines, and other immune-mediating 62 factors responsible for shaping infection, CNS inflammation and disease outcome [7,8]. The 63 evoked immune response contributes to cryptococcal killing by anti-fungal medications and 64 influences cryptococcal fungal burden and host survival [9–11]. Low numbers of leukocytes 65 in CSF are a harbinger of immune suppression and cryptococcal-related mortality [12,13]. Monocytes, the precursors of macrophages that harbor intracellular replication machinery for 66 67 Cryptococcus, show impaired immune activation and function among patients with 68 cryptococcal meningitis with lower probability of survival [14,15]. Increased cryptococcal 69 phagocytosis by macrophages is associated with increased intracellular fungal replication, 70 leading to high CSF cryptococcal fungal burden and lower probability of survival [15]. These 71 earlier observations suggest an influence of cryptococcal and/or other underlying immune 72 suppressive factors that selectively evade T helper (Th) -mediated defense. The evasion of the 73 T cell helper function allows unchecked intracellular fungal replication leading to high fungal 74 burden among patients and a lower probability of recovery.

75 The immune-activated cytokine, chemokine, and checkpoint regulatory responses are 76 important in orchestrating sequestration of Cryptococci in the CNS. The Th1 cytokine 77 interferon (IFN)-y elicits signal transduction to activate intracellular pathogen killing by 78 infected macrophages [16]. The CXCL10-interferon inducible protein 10 (IP-10) supports the 79 recruitment of activated CXCR3<sup>+</sup> T cells and Natural killer (NK) and NK T cells to mediate a 80 Th1-induced immune response [17]. Women with low CSF levels of the CXCR3<sup>+</sup> T cell chemoattractant chemokine, CXCL10 and Th17 T cell-activating cytokine, IL-17A were more 81 82 likely to die on anti-fungal therapy [18]. These observations suggest immune-mediated evasion pressure by such factors that impair cryptococcal host recovery, as seen among patients with 83 84 high fungal burden and diminished immune response.

Casadevall and Pirofski's immune-pathogen damage response framework suggests that an optimal treatment strategy for infectious pathogens should enhance pathogen killing and control the potential detrimental effect of host-induced immune response to infection[19]. However, striking a balance between immune- and antifungal-mediated cryptococcal killing while limiting bystander neuroimmunopathology is a challenge, especially among individuals

with severe immune deficiency [20–22]. To understand immune-associated survival
mechanisms with infiltrating CSF leukocytes, we examined whether the expression of CSF
Th1, Th17 cytokines, and chemokine responses correlate with levels of CSF infiltrating
leukocytes, CSF fungal burden, and host 18-week survival after diagnosis or study enrolment.

94

# 95 **2. Methods**

#### 96 2.1. Parent trial, participants, site, and setting

97 We enrolled 401 consenting adults, 241 males and 160 females, with a median age of 35 years, (interquartile range (IQR); 29-40 years) with cryptococcal meningitis from Mulago 98 99 and Kiruddu Hospitals in Kampala and Mbarara Regional Referral Hospital in Mbarara, 100 Uganda between March 2015 and May 2017. Participants were recruited during the Adjunctive 101 Sertraline for the Treatment of CM trial (ClinicalTrials.gov: NCT 01802385) [23,24]. The 102 CSF cryptococcal antigen (CrAg) lateral flow assay was used to diagnose enrolled patients 103 (Immy Inc., Norman, Oklahoma, USA)[25-27]. Participants or their surrogates provided written informed consent. The Mulago Hospital Research Ethics committee and University of 104 105 Minnesota institutional review board approved the study.

106 The CSF was collected by lumbar puncture. CSF leukocytes were counted in fresh CSF 107 using a hemocytometer. CSF was centrifuged at 500g for 5 minutes and the supernatant 108 separated and cryopreserved at -80 °C before thawing for batch testing.

109

#### 110 **2.2. Study design**

111 This was an exploratory study, designed to investigate the association between the 112 levels of CSF leukocyte infiltration demonstrated by the CSF white cell counts and the 113 associated immune responses at CM diagnosis and 18-week survival after diagnosis or 114 enrolment. Participants were systematically selected and stratified by CSF leukocyte number: 115  $\leq 50/\mu$ L, 51-200 cells/ $\mu$ L, and 201-500 cells/ $\mu$ L.

116

#### 117 2.4. Luminex cytokine and chemokine immunophenotyping

118 The baseline CSF cytokine and chemokine levels were measured using 1:2 dilutions with a 119 human XL cytokine discovery kit per the manufacturer's instructions (R&D, Minneapolis, 120 MN). The Luminex CSF data acquisition was performed at the University of Minnesota earlier 121 explained[18,28]. Briefly, the Th1 cytokines regulated through T-bet and STAT1 transcription factors were TNF-α, IFN-γ, IL-2, and IL-12p70. The Th2 cytokines regulated through Gata 3 122 123 and STAT 6 transcription factor-modulated cytokines were IL-4 and IL-13. The T follicular 124 helper adaptive cells activating cytokines regulated through Bcl-6 and STAT 3 transcription factors were IL-6 and IL-10. The Th17 cytokines include IL-17A. The innate-like cytokines 125 were IL-15, IL-8/CXCL8 or CXCL8, IL-1RA or IL-1F3 produced by innate lymphoid and 126 127 myeloid cells among neutrophils, monocytes, macrophages, dendritic cells to mediate cellular 128 chemoattraction to neuroinflammation.

129 The chemokines that work in synergy with induced cytokines and among activated cells 130 to attract B cells, T cells, and innate lymphoid cells resulting in neuroinflammation were: CXCR3<sup>+</sup> T cell activating chemokine CXCL10/IP-10 secreted by monocytes, macrophages, 131 132 dendritic cells, and in the CNS secreted by microglia cells and astrocytes for lymphocyte 133 chemoattraction to neuroinflammation. The CCL11/Eotaxin for myelocyte chemoattraction to neuroinflammation. The IL-8/CXCL8 for neutrophil activation and chemoattraction to 134 135 neuroinflammation. The immune checkpoint inhibitor was PD-L1/B7-H1 for control of the 136 resultant immune response.

137

#### 138 **2.5. Statistical analysis.**

139 Data were analyzed using GraphPad Prism version 9.3.0 (San Diego, California, USA). 140 In the univariate analyses, continuous variables were analyzed using the Mann-Whitney non-141 parametric unpaired t-test for comparison of sample medians. The difference in survival 142 (binary outcome) was determined using univariate Log-Rank test and multivariate Logistics 143 Regression analysis. The 7.9% (32/401) missingness in survival were systematically imputed 144 using either all alive or dead approach. Kruskal Wallis test (Analysis of variance; ANOVA) 145 was used for simple linear group-wise analysis. Principal Component Analysis (PCA), 146 Multivariate Linear and Logistic Regression and Person Correlation was used for complex 147 multivariate data analysis and data stratification and among the outcome models. The p-value 148 <0.050 at 95% confidence interval (CI) was reported as statistically significant.

149

150 **3. Results** 

151 **3.1. CSF leukocyte infiltration negatively correlates with CSF cryptococcal fungal burden** 

and positively correlate with CSF protein and peripheral CD4<sup>+</sup> and CD8<sup>+</sup> T cell counts.

We defined the baseline participant demographics, clinical, microbiologic, and immunological features that correlated with CSF leukocyte counts (Table 1 and Figure 1). Among participants, 51.5% (206/400) were antiretroviral therapy (ART) experienced, with median CD4<sup>+</sup> T cells/ $\mu$ L of 16 (interquartile range [IQR]; 6-43). The CSF leukocytes were generally low (median of <5 [IQR; <5-45] cells/ $\mu$ L). The CSF cryptococcal fungal colony forming units (CFUs) were at a median of 52,000 (IQR; 1195 to 335,000) CFU/mL.

The baseline participant demographics, clinical, and laboratory features (Table 1) and peripheral blood white blood cells (Figure 1) did not differ by CSF leukocyte stratification (Figure 1 (i)). However, both CSF protein (Figure 1A (ii)) and peripheral CD4<sup>+</sup> and CD8<sup>+</sup> T cells (Figure 1B (i-ii) respectively) correlated positively with CSF WBC number, whereas fungal burden was lower and correlated negatively (Figure 1C) (Pearson r, correlation data not shown). The peripheral white blood cells only had a trend to increasing with CSF white cell stratification (Figure 1 D).

166

# 3.2. CSF cytokines and chemokine concentration positively correlate with CSF leukocytes infiltration

169 Next, we determined the association of CSF cytokine and chemokine concentration in 170 relation to CSF leukocyte infiltration. The level of Th1 cytokines (IL-2, IFN- $\gamma$  and TNF- $\alpha$ 171 correlated with the levels of CSF leukocytes infiltration (Figure 2A (i-iii). Similarly, levels of 172 Th17 cytokine IL-17, the immune regulatory element, IL-10 cytokine and immune checkpoint 173 PD-L1 correlated with CSF leukocytes infiltration (Figure 2A-C), as did the CXCR3<sup>+</sup> T cell 174 chemoattractant chemokine CXCL10/IP-10 and myeloid cells chemoattractant chemokine 175 CCL11/Eotaxin (Figure 2C-D).

176

# 177 3.3. Paucity of cellular and soluble immune activated response is associated with low 178 probability of 18-week survival

The 18-week survival was 55% (203/369 participants). Survival at 18-weeks of observation was associated with CSF leukocyte infiltration (Figure 3). The probability of survival was lowest (151/292 participants; 51.7%) among individuals with CSF leukocytes  $\leq 50 \text{ cells/}\mu\text{L}$  (median  $\leq 5$ ) compared with those with 51-200 (median 110) and 201-500 (median 268) cells/ $\mu\text{L}$  (51% vs. 67.3% vs. 68%, respectively) (Log Rank p=0.028) (Figure 3B). This association of CSF WBC number and survival was consistent with fewer (Figure 3C) and more

WBC strata (Figure 3A) (stratified adjusted Hazard Ratio, (HR= 1.634, 95% CI; 1.140 to 2.343) and p=0.008) (Figure 3C).

- 187Survivors had significantly lower levels of CSF fungal burden/CFUs/mL, (Figure 3 D188(i), high levels of CD4+ and CD8+ T cells and CSF white cells (Figure 3 D (ii)), high levels of189CXCL10, and IL-17A (Figure 3 D (iii) compared to those who died. Other variables IFN-γ,190CSF protein tended to be lower with survival. (Figure 3D (i)). In contrast, PD-L1, TNF-α and191IL-2 tended to be high with survival (Figure 3D (iii)).
- 192

# 3.4. Principal component analysis shows clustering of CSF fungal burden, and host survival with circulating immune response

195 To integrate putative survival-related variables, we visualized the associated data 196 clusters among all participants by Eigenvector projections on principal components (PC) 1 and 197 PC2, respectively (Figure 4). The principal component analysis (PCA) showed three clusters 198 of the cellular and soluble immune factors with fungal burden and host survival by Eigenvector 199 projections on the PCA model (Figure 4A). A diagonal clustering was observed between CSF cryptococcal CFUs/mL and host survival (PCA cluster (i)) and with (CSF white cells, CD4<sup>+</sup> 200 201 and CD8<sup>+</sup> T cells, white blood cells and CSF protein (PCA cluster (ii) (Figure 4A (i-ii)). Two 202 orthogonal clusters were observed for CSF cryptococcal CFUs/mL and host survival with CSF 203 cytokines (PCA cluster (i) and (iii); Figure 4A) and CSF cytokines with CSF and peripheral 204 blood features (PCA cluster (ii) and (iii); Figure 4A) respectively. Cumulatively, the CSF 205 leukocytes Eigenvector projection on PC1 had a 35.7% effect size, and the CSF cryptococcal CFUs/mL Eigenvector projection on PC2 with a 12.8% effect size, contributing the greatest 206 207 variability to the PCA model (Figure 4B). The principal component with highest effect sizes 208 are those with the most likelihood that to predict the model outcome for within component, 209 between components and among components interactions. In this case fungal CFU and CSF 210 WBC was demonstrated to have the greatest prediction power on survival.

211

# 3.5. CSF leukocyte infiltration correlates with circulating CD4<sup>+</sup> and CD8<sup>+</sup> T cells, and CSF fungal burden and levels of IL-17A and TNF-α

Next, we determined the contribution of the cellular and soluble immune factors that independently determine CSF white cells and host survival. After adjusting for PCA components in cluster (ii) with the CSF white cell counts, CSF cryptococcal, Log<sub>10</sub> CFUs/mL; 217 (p=0.0022), CD4<sup>+</sup> T cells counts; (p=0.0119), CD8<sup>+</sup> T cells counts; (p=0.0015), and CSF 218 protein, mg/dL; (p=0.0143), each independently predicted CSF leukocyte infiltration among 219 all patients, (Table 2; Model 1). This observation was consistent even with substitution of 7.9% 220 (32 of 401) missingness in survival (all alive or all dead) (data not shown). After adjusting for 221 PCA components in cluster (iii) with the levels of CSF leukocyte infiltration, the levels of IL-222 17A; (p<0.0001) a Th17 cytokine, and TNF- $\alpha$ ; (p=0.0261) a Th1 cytokine, independently 223 predicted the levels of CSF leukocyte infiltration among all patients, (Table 2; Model 2).

The CSF white cell infiltration during cryptococcal meningitis (cryptococcal CFU/mL) is associated with the number of peripheral circulating CD4<sup>+</sup> and CD8<sup>+</sup> T cells and concentration of CSF protein. These immune modulators together predict the level of IL-17A and TNF- $\alpha$  cytokine concentration in CSF with cryptococcal meningitis.

228

# 229 **3.6. PD-L1, CXCL10 and IL-2 independently predict survival**

230 After adjusting for all components in the PCA outcome model, elevation in levels of 231 B7-H1 / PD-L1 in both linear and logistic regression analysis consistently predicted higher 232 probability of survival (Table 3; Model 1). The higher levels of CXCL10 / IP-10 (model 1-2) 233 consistently and independently predicted higher probability of survival among all patients. 234 (Table 3; Model 1). This observation was consistent even after adjusting for 7.9% missingness 235 in survival (data not shown). The elevation in the levels of IL-2 in both linear and logistic 236 regression analysis (Model 1-2) consistently and independently predicted higher probability of survival among all patient (Table 3; Model 1-2) respectively. Each of the soluble immune 237 238 factors IFN-γ, IL-2, TNF-α, and IL-17A cytokines and CXCL10 / IP-10 chemokine were 239 independently associated with levels of PD-L1, (in all factors multivariate linear regression 240 analysis p<0.020 and data not shown).

241

#### 242 **4. Discussion**

Survival with HIV-associated cryptococcal meningitis is associated with lower CSF fungal burden, greater CSF leukocyte infiltration and higher levels of neuroimmune factors in CSF. We found that individuals with CSF leukocytes <50 cells/µL had the poorest clinical and immunological profile associated with the highest CSF fungal burden, lowest number of peripheral CD4<sup>+</sup> and CD8<sup>+</sup> T cells, CSF cytokines and the lowest probability of 18-week survival than individuals compared with those with >50 CSF leukocytes/µL. Among cytokines

249 in CSF, individuals with CSF leukocytes <50 cells/µL had the lowest levels of the Th1 cellular 250 growth activating cytokine IL-2, cellular activating cytokines IFN- $\gamma$ , cell death activating 251 cytokine TNF-a, and CXCR3<sup>+</sup> T cell chemoattractant chemokine CXCL10 and Th17 T cell-252 activating cytokine IL-17A. In multivariate analysis, infiltrating CSF leukocyte numbers were 253 negatively associated with CSF cryptococcal fungal burden, but positively associated with CSF protein concentration and peripheral circulating CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Moreover, elevated 254 255 concentrations of CXCL10, IL-2 and PD-L1 independently predicted a higher probability of 256 18-week survival.

257 In cryptococcal meningitis, nearly 80% of the baseline CD45<sup>+</sup> WBC in CSF are T cells, 258 among which 70% are CD8<sup>+</sup> and a minority are CD4<sup>+</sup> [8]. Other mononuclear cells central to 259 the CSF exudate included NK cells, monocytes [8] and B cells [7]. Critical to the outcome of 260 cryptococcal infection is the balance of an activated cellular immune response with a poly-261 functional soluble immune profile that function in synergy [29–31]. The primary cells infected 262 are tissue resident macrophages that provide an intracellular niche for cryptococcal replication 263 [29–31]. To prevent intracellular cryptococcal replication requires an activated T cell response. 264 Cytotoxic CD8<sup>+</sup> T cells and NK T cells are modulated by Th1 CD4<sup>+</sup> T cell stimulation [32]. It 265 is notable that evasion of multiple components of innate and adaptive immune system 266 collectively predispose hosts to virulent and lethal cryptococcal disease [29-31]. In this regard, 267 the immune damage response framework suggests that antifungal therapy alone without 268 immune modulatory therapy is not sufficient to cure the infection and modulate host immune-269 mediated injury and death.-Thus, multivariate linear and logistic regression models that 270 integrate cytokine, chemokine, and cellular responses, as described herein, reveal the potential 271 role of poly-functional immune modulated responses to influence fungal burden and host 272 survival.

273 The inverse association of the CSF fungal burden with the levels of cellular and soluble 274 immune response and host survival implicates the selective evasion of Th1- and Th17-mediate 275 control of intracellular Cryptococcus replication. We showed that upregulation of IL-17A is 276 associated with lower CSF cryptococcal fungal burden and improved survival. In the mouse 277 lung model, elevated IL-17 modulates cryptococcal yeast differentiation to limit spread across 278 the blood-brain barrier [33–35]. The adaptive immune clearance of Cryptococcus requires 279 precise activation and recruitment of cytokine- and chemokines-producing T cells that serve as 280 the cornerstones of protection[6]. The evasion of cryptococcal fungal immune control 281 mechanisms with down-regulated Th1 (IFN- $\gamma$ , TNF- $\alpha$ , IL-2) and Th17 T cell cytokines (IL-

17A) and CXCR3<sup>+</sup> T cell chemoattractant chemokine (CXCL10) responses, allows more vigorous replication of *Cryptococcus* and overwhelming infection. Here we report that fatal instances of cryptococcal meningitis are associated with a paucity of CSF CXCR3<sup>+</sup> T cell activating chemokine CXCL10, growth activating cytokine IL-2 and immune checkpoint regulatory element PD-L1. The down regulated expression of these neuroimmune modulatory molecules in cryptococcal disease selectively likely impairs recruitment and maturation of adaptive T cell function in response to the CNS intracellular fungal replication.

289 In this context, Antonia et al., (2019) showed that low concentrations of CXCL10 in 290 circulation were associated with glycoprotein proteolytic cleavage of the CXCL10 chemokine 291 terminal domain by glycoprotein[33]. The effect of the extracellular cleavage of CXCL10 292 ligand also affected other members of the CXCR3<sup>+</sup> receptor family of activating chemokines. 293 These members include CXCL11 and CXCL9 that impair T cell recruitment in response to 294 intracellular evading class of pathogens [33]. Consistent with our results, patients with low 295 levels of CSF CXCL10 and a low probability of survival demonstrate impaired fungal 296 clearance [34] with a high fungal burden [12]. These observations are consistent with a T cell 297 evasion hypothesis in which impaired immune control of intracellular cryptococcal replication 298 is associated with paucity of T cell activated response [31]. Th1 T cell produce IFN-y, TNF-299 α IL-2 activation cytokines and CXCR3<sup>+</sup> T cells CXCL10 chemoattractant enable infiltration 300 of CSF by T, NK, NK-T and myeloid cell lineages [35]. The decrement in CXCR3<sup>+</sup> receptor 301 family chemoattractant chemokines impairs CSF T cell recruitment and cytokine activation at 302 the site of infection, which allows intracellular replication of Cryptococcus resulting in high 303 fungal burden and impaired host recovery.

304 Among Th-1 cytokines, induction of IFN- $\gamma$  facilitates activation and recruitment of 305 effector cellular responses needed to control infection [43]. IFN- $\gamma$  induces the chemokine 306 CXCL10/IP-10, a chemoattractant ligand which recruits activated lymphocytes in response to 307 CNS infection [37,38]. The disruption of IFN- $\gamma$ -encoding genes increased the susceptibility to 308 infection and rapid progression to death [36,39]. Whether mutations in IFN- $\gamma$  encoding genes 309 observed in other infections contribute to the high in hospital mortality rates with Cryptococcal 310 infection has not been investigated [12,13]. Barber et al., demonstrated the importance of IFN-311  $\gamma$  responses in modulating immune activation among intracellular *M. tuberculosis*-infected 312 macrophages [40]. The absence of an IFN- $\gamma$  activating response limited production of reactive 313 oxygen species needed to fully activate intracellular/phagosome killing in infected 314 macrophages with increased mycobacterial burden [40].

Clinically, the low peripheral CD4<sup>+</sup> T cell count despite ART treatment at CM diagnosis potentially implicates the role of ART failure or failed immune reconstitution with unmasking and/or progression of cryptococcal infection. The use of high dose of antifungals early can constitute effective pre-emptive therapy to improve outcomes before patients get severely ill with high CSF cryptococcal fungal burden. However, early diagnosis or staging of cryptococcal infection is a challenge where patients present late with overt disease 1-2 weeks after the onset of symptoms [13,41].

322

# 323 **5.** Conclusion

324 Multiple cellular and soluble immune elements appear to mediate adaptive-innate 325 immune crosstalk to control intracellular cryptococcal replication and modulate host recovery. 326 A paucity of CSF white cells is associated with higher fungal burden, lower levels of neuroimmune cytokines, chemokines and checkpoint inhibitors and a lower frequency of 327 328 survival at 18-weeks. The decrement in these factors likely conspire to limit T cell-mediated 329 control of intracellular cryptococcal replication in macrophages with resultant serious infection 330 and death. The levels of evoked Th1 and Th17A cytokines and CXCR3<sup>+</sup> activating chemokine 331 CXCL10 and PD-L1 immune checkpoint responses are potentially modifiable to enhance 332 clinical outcomes. These variables also serve as diagnostic, prognostic, and survival indicators 333 required to advance immune based therapy to control Cryptococcus and improve survival. 334 Given that antifungal therapy alone is not sufficient to cure cryptococcal meningitis. Immune 335 modulatory treatment may hold promise going forward.

336

### **337 6.** Funding

338 This work was supported in part by the National Institutes of Health and National 339 Institute of Allergy and Infectious Diseases (R01AI078934, R21NS065713, R01AI108479, 340 T32AI055433 - DBM, DRB, and R01 AI108479 - JR), National Institute of Neurologic 341 Diseases and Stroke; (R01NS086312 and R25TW009345, and K24AI096925 - JR). Fogarty International Center training grant; (D43TW009771 - YCM and PhD training scholarship -342 343 SO; R01NS086312 - JR and Northern Pacific Global Health Fellowship Program award (D43TW009345 - LT). GlaxoSmithKline Trust in Science Africa (COL100044928 - SO). 344 345 DELTAS Africa Initiative grant (DEL-15-011 to THRiVE-2 - DBM), Wellcome Trust grant 346 (107742/Z/15/Z - DBM), and Veterans Affairs Research Service; (I01CX001464 - ENJ), the 347 Wellcome Trust (Training Health Researchers into Vocational Excellence (THRiVE) in East

Africa, grant number (087540-DBM). United Kingdom Medical Research Council/Wellcome

349 Trust/Department for International Development (MRC MR/M007413/1 - JR) and the Grand

- 350 Challenges Canada (S4-0296-01 JR). Funding agencies had no role in study design, data
- 351 collection, data analysis, preparation of the manuscript, or the decision to publish.
- 352

# **353 7. Conflict of interest**

Authors have declared no substantial conflict of interest. Authors with funding support have declared and acknowledged sources of funding. SO – was a Fogarty and GlaxoSmithKline-Trust in Science Africa funded doctoral scholar at Infectious Diseases Institute, Makerere University. Part of the work contributed to the doctoral successful doctoral thesis examination at the Department of Medical Microbiology, School of Biomedical Sciences, College of Health Sciences, Makerere University [42]. AMK - was a member of a data safety monitoring board.

360

# **361 8.** Author contribution

362 SO - conceptualized the study, framed the hypothesis, designed statistical models, 363 performed statistical analyses, compiled the results, drafted the first version of the manuscript, 364 edited the manuscript, managed the publication review process, and sourced and contributed 365 research funding. DBM - conceptualized the study, framed the hypothesis, supported 366 experiment design, guided data analysis, guided manuscript writing, contributed to the first draft version of the manuscript, edited the manuscript, sourced, and contributed research 367 funding. ENJ - conceptualized the study, framed the hypothesis, guided data analysis, guided 368 369 manuscript writing, edited the manuscript, sourced, and contributed research funding. YCM -370 conceptualized the study, framed the hypothesis, edited the manuscript, and sourced and 371 contributed research funding. DRB - designed parent cohort studies, guided data analysis, 372 edited the manuscript, sourced, and contributed research funding. JR - conceptualized the 373 study, framed the hypothesis, edited the manuscript contributed to the research funding. OOJ -374 conceptualized the study, framed the hypothesis, and edited the manuscript. LT, CPS EK, 375 AKM, ECO, managed the patients, contributed data, and reviewed the manuscript. AA 376 managed patients' diagnostics, contributed data, and reviewed the manuscript.

377

#### 378 9. Acknowledgments

We thank study participants for their involvement in the parent study. We thank the ASTRO trial team for the clinical management of patients and data collection including Jane Francis Ndyetukira, Cynthia Ahimbisibwe, Florence Kugonza, Alisat Sadiq, Catherine

382 Nanteza, Kiiza Tadeo Kandole, Darlisha Williams, Edward Mpoza, Apio Alison, Radha 383 Rajasingham, Mahsa Abassi, Enock Kagimu, Morris K. Rutakingirwa, Fiona Cresswell, and 384 John Kasibante. We that the doctorial committee mentorship support from Makerere 385 University, especially from Bernard S. Bagaya, Freddie Bwanga, and Henry Kajumbula. We 386 thank institutional support from IDI from Bosco Kafufu, Andrew Kambugu. We thank the 387 Ph.D. program mentorship support received from; the IDI Research Capacity Building Unit 388 especially from Barbara D. Castelnuovo, Aidah Nanvuma, Stephen Okoboi, and the Statistics 389 unit especially Agnes Kiragga. John Hopkins University, School of Medicine and Bloomberg 390 School of Public Health, Department of Molecular Microbiology, and Immunology, especially 391 from Robert R. Bollinger and Arturo Casadevall. From the University of Colorado, Denver, 392 Anschutz Medical Campus Aurora, Division of Infectious Disease, Department of Medicine 393 and Veteran Affairs Research Services especially from Brent Palmer, Tina Powell, and Jeremy 394 Rakhola. We thank the statistical data analysis mentorship received from the University of 395 Minnesota, especially from Ananta S. Bangdiwala and Kathy Huppler Hullsiek.

396

# **397 10. References**

- Molloy SF, Kanyama C, Heyderman RS, Loyse A, Kouanfack C, Chanda D, et al.
   Antifungal combinations for treatment of cryptococcal meningitis in Africa. New
   England Journal of Medicine. 2018;378: 1004–1017. doi:10.1056/NEJMoa1710922
- 401 2. Wake RM, Govender NP, Omar T, Nel C, Mazanderani AH, Karat AS, et al.
  402 Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a
  403 Cryptococcal Antigen Screen-and-Treat Program. Clin Infect Dis. 2020;70: 1683–1690.
  404 doi:10.1093/cid/ciz485
- 405 3. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global
  406 burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.
  407 Lancet Infect Dis. 2017;17: 873–881. doi:10.1016/S1473-3099(17)30243-8
- 408
  4. Nielsen K, Cox GM, Litvintseva AP, Mylonakis E, Malliaris SD, Benjamin DK, et al.
  409
  409
  410
  410
  410
  411
  411
  411
  412
  411
  411
  412
  411
  411
  412
  411
  412
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411
  411</
- 412 5. Santiago-Tirado FH, Onken MD, Cooper JA, Klein RS, Doering TL. Trojan horse transit
  413 contributes to blood-brain barrier crossing of a eukaryotic pathogen. mBio. 2017;8.
  414 doi:10.1128/mBio.02183-16
- 6. Okurut S, Boulware DR, Olobo J, Meya DB. Landmark clinical observations and
  immunopathogenesis pathways linked to HIV and Cryptococcus fatal central nervous
  system co-infection. Mycoses. 2020;63: 840–853. doi:10.1111/myc.13122
- A18
  7. Okurut S, Meya DB, Bwanga F, Olobo J, Eller MA, Cham-Jallow F, et al. B cell
  Compartmentalization in Blood and Cerebrospinal Fluid of HIV-Infected Ugandans
  with Cryptococcal Meningitis. Noverr MC, editor. Infect Immun. 2020;88: e00779-19.
  doi:10.1128/IAI.00779-19
- 422 8. Meya DB, Okurut S, Zziwa G, Rolfes MA, Kelsey M, Cose S, et al. Cellular immune
  423 activation in cerebrospinal fluid from ugandans with cryptococcal meningitis and

- 424 immune reconstitution inflammatory syndrome. Journal of Infectious Diseases.
  425 2015;211: 1597–1606. doi:10.1093/infdis/jiu664
- 426 9. Esher SK, Zaragoza O, Alspaugh JA. Cryptococcal pathogenic mechanisms: A
  427 dangerous trip from the environment to the brain. Mem Inst Oswaldo Cruz. 2018;113:
  428 1–15. doi:10.1590/0074-02760180057
- Mora DJ, Fortunato LR, Andrade-Silva LE, Ferreira-Paim K, Rocha IH, Vasconcelos RR, et al. Cytokine profiles at admission can be related to outcome in AIDS patients with cryptococcal meningitis. PLoS One. 2015;10: 1–17. doi:10.1371/journal.pone.0120297
- 433 11. Wiesner DL, Moskalenko O, Corcoran JM, Mcdonald T, Rolfes MA, Meya DB.
  434 Cryptococcal Genotype Influences Immunological Response and Human Clinical
  435 Outcome after Meningitis. MbioAsmOrg. 2012;3: 1–10. doi:10.1128/mBio.00196436 12.Updated
- 437 12. Jarvis JN, Bicanic T, Loyse A, Namarika D, Jackson A, Nussbaum JC, et al.
  438 Determinants of mortality in a combined cohort of 501 patients with HIV-associated
  439 cryptococcal meningitis: Implications for improving outcomes. Clinical Infectious
  440 Diseases. 2014;58: 736–745. doi:10.1093/cid/cit794
- 441 13. Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, et
  442 al. Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis. New
  443 England Journal of Medicine. 2014;370: 2487–2498. doi:10.1056/nejmoa1312884
- 444 Scriven JE, Graham LM, Schutz C, Scriba TJ, Wilkinson KA, Wilkinson RJ, et al. A 14. 445 glucuronoxylomannan-associated immune signature, characterized by monocyte 446 deactivation and an increased interleukin 10 level, is a predictor of death in cryptococcal 447 meningitis. Journal of Infectious Diseases. 2016;213: 1725–1734. 448 doi:10.1093/infdis/iiw007
- Sabiiti W, Robertson E, Beale MA, Johnston SA, Brouwer AE, Loyse A, et al. Efficient
  phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis.
  J Clin Invest. 2014;124: 2000–2008. doi:10.1172/JCI72950
- 452 16. Barber DL, Andrade BB, Sereti I, Sher A. Immune reconstitution inflammatory
  453 syndrome: the trouble with immunity when you had none. Nat Rev Microbiol. 2012;10:
  454 150–156. doi:10.1038/nrmicro2712
- 455 17. Campanella GSV, Lee EMJ, Sun J, Luster AD. CXCR3 and heparin binding sites of the
  456 chemokine IP-10 (CXCL10). Journal of Biological Chemistry. 2003;278: 17066–17074.
  457 doi:10.1074/jbc.M212077200
- 458 18. Okurut S, Boulware DR, Okafor E, Rhein J, Kajumbula H, Bagaya BS, et al. Divergent neuroimmune signatures in the cerebrospinal fluid predict differential gender-specific survival among patients with HIV-associated cryptococcal meningitis. Front Immunol. 2023;14. doi:10.3389/fimmu.2023.1275443
- 462 19. Casadevall A, Pirofski L. The damage-response framework of microbial pathogenesis.
  463 Nat Rev Microbiol. 2003;1: 17–24. doi:10.1038/nrmicro732
- Casadevall A, Pirofski LA. Host-pathogen interactions: Basic concepts of microbial
  commensalism, colonization, infection, and disease. Infect Immun. 2000;68: 6511–
  6518. doi:10.1128/IAI.68.12.6511-6518.2000
- 467 21. Casadevall A, Pirofski LA. Host-pathogen interactions: Redefining the basic concepts
  468 of virulence and pathogenicity. Infect Immun. 1999;67: 3703–3713.
  469 doi:10.1128/iai.67.8.3703-3713.1999
- 470 22. Shourian M, Qureshi ST. Resistance and tolerance to cryptococcal infection: An
  471 intricate balance that controls the development of disease. Front Immunol. 2019;10: 1–
  472 11. doi:10.3389/fimmu.2019.00066

- 23. Rhein J, Huppler Hullsiek K, Tugume L, Nuwagira E, Mpoza E, Evans EE, et al.
  Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised,
  placebo-controlled, double-blind phase 3 trial. Lancet Infect Dis. 2019;19: 843–851.
  doi:10.1016/S1473-3099(19)30127-6
- 477 24. Rhein J, Morawski BM, Hullsiek KH, Nabeta HW, Kiggundu R, Tugume L, et al.
  478 Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal
  479 meningitis: an open-label dose-ranging study. Lancet Infect Dis. 2016;16: 809–818.
  480 doi:10.1016/S1473-3099(16)00074-8
- 481 25. Boulware DR, Rolfes MA, Rajasingham R, von Hohenberg M, Qin Z, Taseera K, et al.
  482 Multisite validation of cryptococcal antigen lateral flow assay and quantification by
  483 laser thermal contrast. Emerg Infect Dis. 2014;20: 45–53. doi:10.3201/eid2001.130906
- 484 26. Meya DB, Kiragga AN, Nalintya E, Morawski BM, Rajasingham R, Park BJ, et al.
  485 Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive
  486 Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With
  487 CD4 <100 Cells/microL: A Stepped-Wedge, Cluster-Randomized Trial. J Acquir</li>
  488 Immune Defic Syndr. 2019;80: 182–189. doi:10.1097/QAI.000000000001894
- 489 27. Dyal J, Akampurira A, Butler E, Kiggundu R, Nabeta H, Musubire A, et al.
  490 Reproducibility of CSF quantitative culture methods for Cryptococcus neoformans.
  491 International Journal of Infectious Diseases. 2014;21: 286.
  492 doi:10.1016/j.ijid.2014.03.1013
- 493 28. Stadelman AM, Ssebambulidde K, Tugume L, Pastick KA, Hullsiek KH, Lofgren S, et
  494 al. Impact of biological sex on cryptococcal meningitis mortality in Uganda and South
  495 Africa. Med Mycol. 2021;59: 712–719. doi:10.1093/mmy/myaa108
- 496 29. Rohatgi S, Pirofski LA. Host immunity to Cryptococcus neoformans. Future
  497 Microbiology. Future Medicine Ltd.; 2015. pp. 565–581. doi:10.2217/fmb.14.132
- 498 30. Ma H, May RC. Chapter 5 Virulence in Cryptococcus Species. Advances in Applied
  499 Microbiology. 2009. pp. 131–190. doi:10.1016/S0065-2164(08)01005-8
- 50031.Gibson JF, Johnston SA. Immunity to Cryptococcus neoformans and C. gattii during501cryptococcosis. Fungal Genetics and Biology. 2015;78: 76–86.502doi:10.1016/j.fgb.2014.11.006
- 32. Barb AW. Fc γ receptor compositional heterogeneity: Considerations for
   immunotherapy development. Journal of Biological Chemistry. American Society for
   Biochemistry and Molecular Biology Inc.; 2021. doi:10.1074/jbc.REV120.013168
- 33. Antonia AL, Gibbs KD, Trahair ED, Pittman KJ, Martin AT, Schott BH, et al. Pathogen
  Evasion of Chemokine Response Through Suppression of CXCL10. Front Cell Infect
  Microbiol. 2019;9. doi:10.3389/fcimb.2019.00280
- Solaria State
  Solaria State
- 514 35. Chung SH, Ye XQ, Iwakura Y. Interleukin-17 family members in health and disease.
  515 International Immunology. Oxford University Press; 2021. pp. 723–729.
  516 doi:10.1093/intimm/dxab075
- 517 36. Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases. Biomol Concepts. 2018;9: 64–79. doi:10.1515/bmc-2018-0007
- 519 37. Vazirinejad R, Ahmadi Z, Arababadi MK, Hassanshahi G, Kennedy D. The biological functions, structure and sources of CXCL10 and its outstanding part in the pathophysiology of multiple sclerosis. Neuroimmunomodulation. 2014;21: 322–330. doi:10.1159/000357780

- 38. Oslund KL, Zhou X, Lee B, Zhu L, Duong T, Shih R, et al. Synergistic up-regulation of
  CXCL10 by virus and IFN γ in human airway epithelial cells. PLoS One. 2014;9: 1–8.
  doi:10.1371/journal.pone.0100978
- 39. Naik B, Ahmed SMQ, Laha S, Das SP. Genetic Susceptibility to Fungal Infections and
  Links to Human Ancestry. Front Genet. 2021;12: 1–12. doi:10.3389/fgene.2021.709315
- 528 40. Daniel L. Barber. Immune reconstitution inflammatory syndrome: the trouble with none. 529 immunity when you had Nat Rev Microbiol. 2013;23: 1 - 7. 530 doi:10.1038/nrmicro2712.Immune
- 41. Poplin V, Boulware DR, Bahr NC. Methods for rapid diagnosis of meningitis etiology
  in adults. Biomarkers in Medicine. Future Medicine Ltd.; 2020. pp. 459–479.
  doi:10.2217/bmm-2019-0333
- 534 42. Okurut S. B cell responses, immune modulation, and survival among patients with HIV 535 associated cryptococcal meningitis. Doctoral thesis, Makerere University. 2023.
- 536
- 537

# 539 Tables

# 540 Table 1. Participants Baseline Demographics and Clinical Features by CSF Leukocytes

541

Baseline	≤50 white	51-200 white	201-500 white	D
Demographics	cells/µL CSF	cells/µL CSF	cells/µL CSF	P-value
Ν	318	57	26	
Age, years	35 (29-41)	32 (29-38)	33 (28-39)	0.227
Females, n (%)	127 (39.9)	22 (39.6)	11 (42.3)	0.950
Weight, kg	51.5 (50-60)	55 (50-60)	50 (49.5-60)	0.428
Months on ART*	10.0 (1.3-39.5)	6.4 (1.2-38.6)	2.7 (0.4-4.5)	0.132
Headache duration,	14 (7-30)	14 (7.5-30)	14 (7-23.3)	0.924
days				
GCS <15, n (%)	146 (67.3)	29 (50.9)	17 (65.4)	0.149
Hemoglobin, g/dL	11.7 (10.1-13.3)	11.4 (10.1-13.6)	10.5 (9.2-12.4)	0.127
Platelets, $x10^{3}/\mu L$	192	203	225.5	0.258
	(132-251)	(145-254)	(136 - 329)	
CSF opening pressure,	19.7 (14.7-22.1)	17.7 (13.2-20.9)	19.1 (15.3-20.1)	0.653
mm Hg				

542

Values are median (IQR). Statistic: Kruskal Wallis test (ANOVA) comparing the variables 543 544 among participants across the three CSF white cell class intervals. Not statistically significant 545 were variables with p-value  $\geq 0.05$  at a 95% confidence interval. ART\* experience antiretroviral therapy; reported among 165 participants with  $\leq 50$  cells/µL white cells, 32 546 547 participants with 51-200 white cells/µL, and 14 participants with 201-500 white cells/µL. GCS 548 - Glasgow Coma Scale. CFU -colony forming units in CSF cryptococcal fungal growth culture. 549 Normal adults CSF opening pressure is <10-15 mmHg that shows generally high CSF opening pressure above normal among patients with cryptococcal meningitis. 550

# 551 Table 2. Multivariate Linear Regression of Independent Predictors of CSF Leukocytes

### 552 Infiltration

Independent	Estimated Risk Ratios (95%)	Dependent	P value		
adjusted variables	CI; asymptotic)				
Model 1: (PC1; (ii)) CSF white cell dependent and matched independent colinear predictor					
variables. Adjusted for PCA cluster (ii) components; (CSF cryptococcal, log10 CFUs/mL,					
CD4 <sup>+</sup> T cells / $\mu$ L, CD8 <sup>+</sup> T cells / $\mu$ L, CSF protein, mg/dL, and blood white cells / $\mu$ L).					
CSF cryptococcal,	-8.11 (-13.28 to -2.94)	CSF white cells	0.002		
log10 CFUs/mL					
$CD4^+$ T cells /µL	0.28 (0.06 to 0.50)	CSF white cells	0.012		
$CD8^+$ T cells /µL	0.05 (0.02 to 0.078)	CSF white cells	0.002		
CSF protein, mg/dL 0.09 (0.02 to 0.16)		CSF white cells	0.014		
Model 2: PC1; (iii) CSF white cell dependent and matched independent colinear predictor					
variables. Adjusted for PCA cluster (iii) components; (B7-H1 / PD-L1, CCL11 / Eotaxin,					
CXCL10 / IP-10, IFN-γ, IL-10, IL-17A, IL-2 and TNF-α)					
IL-17A	3.04 (1.97 to 4.12)	CSF white cells	< 0.0001		
TNF-α	-0.16 (-0.29 to -0.02)	CSF white cells	0.026		

# 553

554 Statistic: Multivariate Linear Regression (least squares) models among all participants. 555 Cytokines; (pg/mL). The values (Risk Ratios) - shown model transformed and normalized 556 imputed values (not actual measurements) of variables. P values, p<0.0500 are statistically 557 significant. Other variables including peripheral white blood cells, PD-L1, CXCL10, CCL11, 558 IFN- $\gamma$ , IL-2 and IL-10 did not independently predict the levels of CSF white cells with 559 cryptococcal meningitis.

560

561

562

# 564 Table 3. Multivariate Linear and Logistic Regression of Independent Predictors of

# 565 Survival.

Independent	<b>Estimated Risk Ratios</b>	Linear	Logistic regression;	
adjusted	(95% CI)	regression,	Odds Ratios (95% CI)	
variables		P value		
Model 1: All Principal Components survival dependent and matched independent predictor of				
survival. Adjusted for CSF white cells / $\mu$ L, CSF cryptococcal log10 CFUs /mL, CD4 T cells / $\mu$ L,				
CD8 <sup>+</sup> T cells /µL, CSF protein, mg/dL, B7-H1 / PD-L1, CCL11 / Eotaxin, CXCL10 / IP-10, IFN-				
$\gamma$ , IL-10, IL-17A, IL-2, TNF- $\alpha$ and blood white cells / $\mu$ L.				
B7-H1 / PD-L1	0.0010 (4.1e-005 to 0.0021)	0.0414	1.0060 (1.0010 to 1.0110)	
CXCL10 / IP-10	-0.0001 (-0.0001 to -5.4e-006)	0.0320	0.9997 (0.9995 to 1.0000)	
IL-2	0.0280 (0.0054 to 0.0507)	0.0155	1.1430 (1.0330 to 1.2720)	
Model 2: PC2: PCA cluster (iii) survival dependent and matched independent predictor variables.				
Adjusted for (B7-H1 / PD-L1, CCL11 / Eotaxin, CXCL10 / IP-10, IFN-γ, IL-10, IL-17A, IL-2				
and TNF-α)				
CXCL10 / IP-10	-0.0001 (-0.0001 to -2.1e-005)	0.0045	0.9997 (0.9995 to 0.9999)	
IL-2	0.0207 (0.0014 to 0.0399)	0.0353	1.0920 (1.0080 to 1.1870)	

566

Statistic: Multivariate Linear Regression (Least Squares) and Multivariate Logistic Regression 567 Survival outcome dependent predictor variables among all participants. Interpretation: the 568 569 values (Risk Ratios and Odds Ratios) - shown model transformed and normalized imputed 570 values (not actual measurements) of variables. In Linear regression, the p-values, p<0.0500 were statistically significant. CI - confidence interval. The confidence interval values not 571 572 crossing through zero on either direction (positive or negative) are statistically significant. The 573 PCA cluster (ii) adjusted components including (CSF white cells, CSF cryptococcal log10 574 CFUs, CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, CSF protein, and blood white cells) and other variables did 575 not predict or match survival in either analyses (model analysis data not shown).

576

#### 578 Figure and Figure Legends

#### 579 Figure 1

#### 580



**Figure 1. the correlation of CSF and blood clinical features.** A - correlation of CSF features with 18 weeks survival by levels of CSF white cells. A (i) – CSF white cells, A (ii) – CSF proteins and A (iii) CSF cryptococcal fungal burden. B – correlation of peripheral blood features with 18 weeks survival by levels of CSF white cells. B (i) – peripheral blood white cells, B (ii) - CD4<sup>+</sup> T cells, and B (iii) - CD8<sup>+</sup> T cells. Error bars – median and 95% confidence intervals. \* - statistically significant variables reported at p-value <0.050, at 95% confidence intervals.

- 590
- 591
- 592
- 593



595



597

598 Figure 2. Correlation of CSF cytokines and chemokine levels with CSF leukocyte counts 599 A- Th1 cytokines; A (i) - Interleukin 2, A (ii) - Interferon gamma, A (iii) - Tumor necrosis 600 factor alpha. B - Th17 cytokine, IL-17A. C – Immune regulatory elements; (i) – Interleukin 10, 601 and programmed death 1 ligand. D Chemokines; D (i) CXCL10/IP-10 and D (ii) -CCL11/Eotaxin. The CSF white cells; ( $\leq$ 50 cells/ $\mu$ L; n=318), (51-200 cells/ $\mu$ L; n=57) and 602 603 (201-500 cells/µL; n=26) participants. Error bars - median and 95% confidence intervals. \* -604 statistically significant variables reported at p-value <0.050, at 95% confidence intervals. 605





610	Figure 3. correlation of CSF white cells with 18-week survival. A -survival by CSF white
611	cell intervals (<5; n=245), (5-20; n=31), (21-50; n=42), (51-100; n=26), (101-200; n=31), and
612	(201-500; n=26). B - 18 weeks survival by CSF white cells; ( $\leq$ 50 cells; n=318), (51-200)
613	cells/ $\mu$ L; n=57) and (201-500 cells/ $\mu$ L; n=26) participants. C – 18-week survival with CSF $\leq$ 50
614	cells/ $\mu$ L. D (i-iii) –illustrates univariate immune responses associated with survival between
615	survivors and those who died during 18-weeks of follow-up. Statistics - Mann-Whitney
616	unpaired t-test. * - show statically significant variables. NS- not significant. Error bars - show
617	95% confidence intervals. p-values, p<0.050 were statistically significant.

#### 619 Figure 4



Figure 4. Principal Component Analyses showing Eigenvector projection (A) and 621 622 cumulative effect size contributed by each covariate the PCA model (B) examined among 623 all participants. The three planes demonstrated by the Eigenvector projects are; (i-ii) -624 diagonal plane between CSF fungal burden and host survival and CSF white cells, CSF protein, peripheral white cells, CD4<sup>+</sup> and CD8<sup>+</sup> T cells. (i-iii) orthogonal plane between CSF fungal 625 626 burden and host survival and the cytokine/chemokine profile. (ii-iii) orthogonal plane between 627 CSF fungal burden and host survival and CSF white cells, CSF protein, peripheral white cells, CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Eigenvectors >5 shows greater power and association with the 628 629 outcome variable among interacting covariates.

630